Фармакоэпидемиологическое и фармакоэкономическое исследование терапии ВИЧ-инфекции
Приверженность к лечению пациентов с ВИЧ-инфекцией находится на низком уровне — 74,1%, что отрицательно сказывается на прогнозе заболеванияведущими факторами, отрицательно влияющими на приверженность, являются отсутствие работы, употребление психоактивных веществ и кратность приема антиретровирусных препаратов более 2 раз в сутки. К управляемым факторам, отрицательно влияющим на результаты… Читать ещё >
Содержание
- Список сокращений
Глава 1. Социальное, эпидемиологическое, экономическое значение ВИЧ-инфекции и основные подходы к лечению (обзор литературы)
1.1. Этиология и эпидемиология ВИЧ-инфеции
1.2. Фармакоэпидемиологические аспекты ВИЧ-инфекции
1.2.1. Развитие антиретровирусной терапии
1.2.2. Основные принципы антиретровирусной терапии
1.2.2.1. Препараты первой линии
1.2.2.2. Препараты второй линии
1.2.2.3. Резервные схемы терапии
1.2.2.4. Монотерапия
1.2.2.5. Плановый перерыв в лечении
1.2.2.6. Синдром восстановления иммунитета
1.3. Время начала антиретровирусной терапии
1.4. Лекарственная устойчивость ВИЧ
1.5. Оценка эффективности антиретровирусной терапии
1.6. Будущее антиретровирусной терапии
1.7. Влияние приверженности к терапии на результаты лечения
1.7.1. Приверженность и антиретровирусная терапия
1.7.2. Факторы, определяющие приверженность к лечению
1.7.3. Методы повышения приверженности
1.7.4. Методы оценки приверженности
1.8. Ко-инфекция ВИЧ/вирусный гепатит С
1.8.1. Взаимное влияние ВИЧ и вируса гепатита С
1.8.2. Ведение пациентов с ВИЧ/вирусный гепатит С
1.9. Побочные эффекты антиретровирусных препаратов
1.9.1. Классификация побочных эффектов
1.9.2. Характеристика побочных эффектов
1.10. Фармакоэкономические аспекты антиретровирусной терапии
1.11. Резюме
Глава 2. Материалы и методы
2.1. Клиническая характеристика больных
2.2. Методы обследования больных
2.2.1. Клинический осмотр и методика опроса пациентов
2.2.2. Лабораторные методы
2.2.3. Методика анкетирования пациентов
2.2.4. Анализ медицинской документации
2.2.5. Методика оценки качества жизни
2.2.6. Фармакоэпидемиологическое исследование
2.2.7. Методы клинико-экономического исследования
2.2.7.1. Определение затрат
2.2.7.2. Анализ «стоимость-эффективность»
2.2.7.3. Анализ «стоимость-полезность»
2.2.7.4. Методика ABC, VEN анализа
2.2.8. Математическое моделирование
2.3. Методы статистической обработки
Глава 3. Фармакоэпидемиологическая характеристика терапии ВИЧ-инфеции
3.1. Частота применения и средние дозы использованных препаратов
3.2 ABC, VEN и частотный анализ лекарственных назначений
3.3 Определение доли отечественных АРВ-препаратов в структуре общих затрат
3.4. Оценка качества проведения антиретровирусной терапии у пациентов группы Б
3.5. Определение прироста С04-клеток в зависимости от времени начала антиретровирусной терапии
3.6. Оценка комплаентности пациентов группы Б к антиретровирусной терапии
3.7. Оценка соответствия стандарту проводимой терапии ВИЧ-инфекциии
3.8. Резюме
Глава 4. Оценка эффективности и безопасности терапии ВИЧ-инфекции
4.1. Сравнительная оценка эффективности препаратов группы ННИОТ (эфавиренц) и ИП (лопинавир/ритонавир)
4.1.1. Динамика уровня С04-клеток и вирусной нагрузки
4.1.2. Влияние приверженности на результаты лечения
4.2. Оценка качества жизни пациентов, получающих АРВТ
4.3. Оценка безопасности проводимой терапии
4.4. Сравнительная оценка частоты назначений препаратов различных классов у пациентов исследуемых групп
4.5. Определение факторов, влияющих на результаты лечения
4.6. Резюме
Глава 5. Фармакоэкономическая оценка эффективности лечения ВИЧ-инфекции
5.3.1. Расчет стоимости болезни
5.3.2. Расчет коэффициентов «стоимость-эффективность» и «стоимость-полезность»
5.3.3. Моделирование расходов на лечение ВИЧ-инфекции
Резюме
Список литературы
- Белозеров Е.С., Буланьков Ю. И. ВИЧ-инфекция. Изд-во Джангар. -2006. — 224 с.
- ВИЧ-инфекция и СПИД. Клинические рекомендации: // Под ред. В. В. Покровского. М.: ГЭОТАР-Медиа. — 2006. — 128 с.
- ВИЧ-инфекция: клиника, диагностика и лечение. //В. В. Покровский с соавт. М. — 2003. — С.375 — 404.
- Войтова Д. И., Чайка Н. А., Рахманова А. Г. Микобактериоз и СПИД. -СПб.: СППО-2, 1991.-28 е., ил.
- Государственный Совет РФ. О состоянии эпидемии ВИЧ/СПИДа в Российской Федерации и мерах по противодействию ее распространению. Москва, 2010. 1
- Запорожан В.Н., Аряев Н. Л. ВИЧ-инфекция и СПИД. — К.: Здоров’я. -2004. 624 с.
- Краткое клиническое руководство по паллиативной помощи при ВИЧ-СПИДе // Под ред. Новикова Г. А. М. 2005. — 131 с.
- Лечение и помощь при ВИЧ/СПИДЕ. Клинические протоколы для Европейского региона. ВОЗ, 2007.
- Материалы IX съезда всероссийского научно-практического общества эпидемиологов, микробиологов и паразитологов. Москва, 2007, с.303−304.
- Материалы семинара по ВИЧ-инфекции, Алмата, 13 октября 2008 г., Москва, 24 октября 2008 г., данные федерального научно-методического центра по борьбе со СПИД Роспотребнадзора.
- П.Мирошниченко А. В. ВИЧ-инфекция на стадии первичных проявлений: особенности клинической картины, диагностики и антиретровирусной терапии: автореф. дис.. канд. мед. наук. М, 2005, 24 с.
- Мультипрофессиональный подход влечении и уходе за людьми, живущими с ВИЧ-СПИДом. Практика совместного консультированияи лечения. POO «СПИД инфоевязь». Руководство. / Под ред. Островского Д. В. М.: 2006, 212 с.
- И.Покровский В. В. Эпидемиология и профилактика ВИЧ-инфекции и СПИД. М.: Медицина, 1996. — 248 е.: ил.
- Покровский В. В., Юрин О. Г., Кравченко А. В. Краткое руководство по лечению ВИЧ-инфекции.- М -2005. с. 27 71.
- Покровский В.И. Клинические рекомендации. ВИЧ-инфекция и СПИД. М.: ГЭОТАР-Медиа, 2007. 198 с.
- Покровский В.В. ВИЧ-инфекция и СПИД: клинические рекомендации. -М.: Изд. гр. «ГОЭТАР-Медиа», 2006. с. 16−20.
- Пригожина В. К., Чайка Н. А., Рахманова А. Г. Герпетическая инфекция и СПИД. Л.: Ленуприздат, 1990. — 42 е., ил.
- Приказ МЗ РФ № 163 от 27.08.2002 «Об утверждении отраслевого стандарта «Клинико-экономические исследования. Общие положения» // Проблемы стандартизации в здравоохранении. 2002. Вып. 5: с. 56 -65.
- Рахманова А. Г., Исаков В. А., Чайка И. А. Цитомегаловирусная инфекция и СПИД. Л.: Ленуприздат, 1990. — 64 е., ил.
- Рахманова А. Г., Белоусов Ю. Б., Гуревич К. Г. и соавт. Основы анти-ретровирусной терапии. Методические рекомендации. М., 2006. 138 с.
- Рахманова А.Г. ВИЧ-инфекция. СПб, 2004 — 696 с.
- Сборник нормативно-правовых актов и методических документов по вопросам диагностики, лечения, эпидемиологического и поведенческого надзора ВИЧ/СПИД и сопутствующих заболеваний. Минздравсоцразвития РФ, М., 2007.
- Сердюков А.Г., Таджиева И. И. Оказание медицинской помощи ВИЧ-инфицированным больным. М.: 2007, 121 с.
- Смольская Т. Т., Лещинская Н. П., Шилова Э. А. Серологическая диагностика ВИЧ-инфекции. СПб.: СППО-2, 1992. — 81 с.
- СПИД: синдром приобретенного иммунного дефицита / П. Г. Рытик, А. Г. Коломиец, Н. Д. Коломиец. Мн.: Беларусь, 1988. — 127 е., 2 л. ил.: ил.
- Фармакоэкономика и фармакоэпидемиология практика приемлемых решений / Под редакцией В. Б. Герасимова, A. JI. Хохлова, О. И. Карпова. — М.: Медицина, 2005ю — 352 е.: ил.
- Чайка Н. А., Клевакин В. М. СПИД: чума XX века. JL: Лениздат, 1989.- 111 е., ил.
- Шувалова Е. П. Тропические болезни. СПб-2004. С. 180 — 182.
- Ягудина Р.И., Куликов А. Ю. Фармакоэкономика: общие сведения, методы исследования // Новая аптека. 2007. — № 9. — С. 73−78. (6)
- Ягудина Р.И., Куликов А. Ю., Литвиненко М.М. QALY: История, методология и будующее метода // Фармакоэкономика. 2010. — № 1. — (7)
- Abadi J, Sprecher E, Rosenberg MG, et al: Partial treatment interruption of protease inhibitor-based highly active antiretroviral therapy regimens in HIV-infected children // J. Acquir. Immune Defic. Syndr. 2006. — 41:298 303.
- Abbot’s new Kaletra tablet gets EMEA CHMP s OK. Therapeutics Daily, 8 May 2006 (http: //www.therapeuticsdaily.com/News/article.cfm &contenttype=sentryarticle& contentvalue=884 529&channelI D=31, accessed 9 May 2006).
- Ackerman Z., Ackerman E., Paltiel O. Interfamilial transmission of hepatitis C virus: a systematic review // Journal of Viral Hepatology. 2000. -7(2):93−103.
- Alberti A., et al. Short statement of the first European Consensus Conference on the Treatment of Chronic Hepatitis B and C in HIV Coinfected Patients // Journal of Hepatology. 2005. — 42(5):615−624.
- Aleman S. et al. Drug resistance at low viraemia in HIV-1 infected patients with antiretroviral combination therapy // AIDS. 2002. — 16:1039−1044.
- Alter M.J. Epidemiology of viral hepatitis // Journal of Hepatology. 2006. — 44(S1):S6-S9.
- Altice F.L., Mostashari F., Friedland G.H. Trust and the acceptance of and adherence to antiretroviral therapy // Journal of Acquired Immune Deficiency Syndromes. 2001. — 28(l):47−58.
- Ananworanich J., et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial // Lancet. 2006. — 368: 459−65
- Attia S., et al. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis // AIDS. 2009 Apr 17.
- Baker J.V., et al. CD4+ count and risk of nonAIDS diseases following initial treatment for HIV infection // AIDS. 2008. — 27, 841−848.
- Bamberger J.D., et al. Helping the urban poor stay with antiretroviral HIV drug therapy // American Journal of Public Health. 2000. -, 90(5):699−701.
- Bangsberg D.R., et al. Provider assessment of adherence to HIV antiretroviral therapy // J Acquir Immune Defic Syndr. 2001. — 26(5):435142.
- Bangsberg D.R., Perry S., Charlesbois E.D. Adherence to HAART predicts progression to AIDS // 8th Conference on Retroviruses and Opportunistic Infections (CROI), Chicago, 4−8 February 2001 (Abstract 483).
- Bani-Sadr F., Bedossa P., Rosenthal E., at al. Does Early Antiretroviral Treatment Prevent Liver Fibrosis in HIV/HCV-Coinfected Patients? // AIDS. 2009. — 50(2): 234−236.
- Bannister W.P., Kirk O., Gatell J.M., et al. Regional Changes Over Time in Initial Virologie Response Rates to Combination Antiretroviral Therapy Across Europe // J. Acquir. Immune Defic. Syndr. 2006. — 42: 229 — 237.
- Barbara H. McGovern, et al. Managing Symptomatic Drug-Induced Liver Injury in HIV-Hepatitis C Coinfected Patients: A Role for Interferon // Clin. Infect. Dis. 2007. — 45, 1386−1392.
- Barrios A., et al. Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine // AIDS. -2005. 19(6):569 — 575.
- Bartlett J.A. Addressing the challenges of adherence review. J Acquir Immune Defic Syndr. 2002. — 29 Suppl. 1: S2-S10.
- Bartlett J.A., et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1-infected adults // AIDS. 2001. -15(11): 1369—1377.
- Bartlett J.G. Pocket guide to adult HIV/AIDS treatment. Baltimore, Johns Hopkins University AIDS Services. 2006- 20 — 60.
- Bartlett J.G., Gallant J.E. 2003 Medical Management of HIV Infection. Baltimore, Johns Hopkins University, Division of Infectious Disease and AIDS
- Service, 2003 (http://www.hopkins-aids.edu/publications/book/03MMHIV1 to3 .pdf, accessed 11 September 2006).
- Behler M.C., et al. Hematologic Toxicity Associated with Interferon-Based Hepatitis C Therapy in HIV Type 1-Coinfected Subjects // Clin. Infect. Dis. -2007.-44:1375−83.
- Benhamou Y., et al. Liver fibrosis progression in HIV-HCV coinfected patients // The Multivirc Group. Hepatology. 1999. — 30:1054−1058.
- Berengue J., et al. Association between Exposure to Nevirapine and Reduced Liver Fibrosis Progression in Patients with HIV and Hepatitis C Virus Coinfection // Clin. Infect. Dis. 2008. — 46 (1), 137−143.
- Berg T., von Wagner M., Nasser S., et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin // Gastroenterology. 2006. — 130, 1086 — 1097.
- Bhaskaran K., et al. Changes in the Risk of Death After HIV Seroconversion Compared With Mortality in the General Population // JAMA. 2008. — 300, 51−59.
- Bonacini M., et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV international panel // J. Acquir. Immune Defic. Syndr. 2007. — 45, S38 — S46.
- Bradley H.C., et al. Detection of Nonnucleoside Reverse-Transcriptase Inhibitor Resistant HIV-1 after Discontinuation of Virologically Supressive Antiretroviral Therapy // Clin. Infect. Dis. 2008. — 47, 421 — 424.
- Brau N., Salvatore M., Rhos-Bedoya C., et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV supression using antiretroviral therapy // J. Hepatol. 2006. — 44, 47 — 55.
- British HIV Assosiation guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy- 2008, BG Gazzard Guideliness Writing Group.
- Calmy A., Lange J., Battegay M., et all. Nevirapine Administered Once Daily Is as Efficient as a Twice-daily Dosing. A Collaborative Cohort Study // 15th Conference on Retroviruses and Opportunistic Infecions, 2009, Boston.
- Cane P., et al. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study // BMJ. 2005. -331(7529): 1368.
- Carrat F., et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial // JAMA. 2004. — 292:2839−2848.
- Carrieri M.P., et al. Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up study // Antiviral Therapy. 2003. — 8(6):585−594.
- Carrieri P., et al. The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort // J. Acquir. Immune Defic. Syndr. 2001. — 28(3):232−239.
- Castro A. Adherence to antiretroviral therapy: merging the clinical and social course of AIDS // PloS Med. 2005. — 2, e338.
- Centers for Disease Control. Twenty-five years of HIV/AIDS-United States, 1981 2006 // MMWR Morb. Mortal. Wkly. Rep. — 2006. — 55- 589 — 592.
- Chander G., Lau B., Moore R.D., et al. Hazardous Alcohol Use: A Risk Factor for Non-Adherence and Lack of Suppression in HIV Infection // J. Acquir. Immune Defic. Syndr. 2006. — 43:411 — 417.
- Charles D. Wells et al. HIV Infection and Multidrug? Resistant Tuberculosis The Perfect Storm // The Journal of Infectious Diseases. — 2007. — 196, S86-S107.
- Chesney M., Ickovics J., Hecht F., et all. Adherence: a necessity for successful HIV combination therapy // AIDS. 1999. — 13 (Suppl. A), S271 — S278.
- Chesney M., Morin M., Sherr L. Adherence to HIV combination therapy // Soc. Sei. Med. 2000. — 50, 1599 — 1605.
- Chesney M.A. Factors Affecting Adherence to Antiretroviral Therapy // Clin. Infect. Dis. 2000. — 30(Suppl 2):S171-S176.
- Chung R.T., et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons // N. Engl. J. Med. 2004. — 351:451−459.
- Cingolani A., et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA) // AIDS. 2002. — 16(3):369−379.
- Claxton A.J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance // Clinical Therapeutics. 2001. — 23(8):1296—1310.
- Cloted B., et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomized trials // Lancet. -2007.-369, 1169−1178.
- Colleen F. Kelley, et al. Incomplete Peripheral CD4+ Cell Count Restoration in HIV-infected Patients Receiving Long-Term Antiretroviral Treatment // Clin. Infect. Dis. 2009. — 48:787−94.
- Cook R.L., Sereika S.M., Hunt S.C., et al. Problem Drinking and medication adherence among persons with HIV infection // J Gen Intern Med. 2001. -16:83−88.
- Corbau R., Mori J., Phillips C., et al. Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1 // Antimicrob Agents Chemother. 2010. -54(10): 4451−4463
- Coutinho A., Ekwaru J., Were W., et al. Utility of Routine Viral Load, CD4 Cell Count, and Clinical Monitoring among HIV-infected Adults in Uganda: A Randomized Trial // 15th Conference on Retroviruses and Opportunistic Infections- 2008- Boston.
- Croda J., et al. Benefit of antiretroviral therapy on survival of human immunodeficiency virus-infected patients admitted to an intensive care unit // Crit. Care Med.-2009.-37(5), 1605−1611.
- Croom K.F., Keam S.J. Tipranavir: a ritonavir-boosted protease inhibitor // Drugs. 2005. — 65(12):1669 — 1679.
- Crum N., et al. Comparison of Causes of Death in Persons with HIV: Pre-, Early, and Late HAART Era // J. Acquir. Immune Defic. Syndr. 2006. -41:194−200.
- Curtis L. Cooper. De-Livering HIV/Hepatitis C Virus-Coinfected Patients from Antiretroviral Hepatotoxity // The Journal of Infectious Diseases. -2007. 196: 650−658.
- Daar E.S., Richman D.D. Confronting the emergence of drug-resistant HIV type 1: impact of antiretroviral therapy on individual and population resistance // AIDS Research and Human Retroviruses. 2005. — 21(5):343 — 357.
- Danel C., Moh R., Minga A., et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa Trivacan ANRS 1269 trial: a randomised trial // Lancet. 2006. -367(9527): 1981 -9.
- DART Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1 infected adults in Africa // AIDS. 2006. — 20:1391 — 1399.
- David A. Cooper, Roy T. Steigbigel, Jose M. Gatell, et al. Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection // N. Engl. J. Med. 2008. -359:355−65.
- David R. Bangsberg. Less Than 95% Adherence to Nonnucleoside Reverse-Transcriptase Inhibitor Therapy Can Lead to Viral Suppression // Clin. Infect. Dis. 2006. — 43:939−41
- De Mendoza C., et al. Antiretroviral recommendations may influence the rate of transmission of drugresistant HIV type 1 // Clin. Infect. Dis. -2005. -41(2):227- 232.
- De Mendoza C., et al. Evidence for a different transmission efficiency of viruses with distinct drugreistance genotypes // 12th International Drug Resistance Workshop, Los Cabos, Mexico, 10−13 June 2003 (Abstract 130).
- Descamps D., et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy // JAMA. 2000. — 283(2):205-l 1.
- El-Sadr W., et al. Episodic CD4-guided use of art is inferior to continuous therapy: results of the SMART study // 13th Annual Conference on Retroviruses and Opportunistic Infections (CROI), Denver, 5−8 February 2006 (Abstract 106LB).
- El-Sadr W., et al. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, CD4+ count-guided interruption of antiretroviral treatment // N. Engl. J. Med. 2006. — 355 (22), 2283 — 2296.
- Emery S., Neuhaus J.A., Phillips A.N., et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving
- ART at baseline in the SMART study // J Infect Dis. 2008. — 197(8): 113 344.
- EUROHIV. HIV AIDS Surveillance in Europe: End-year report 2004, No.71 available at http://www.eurohiv.org/reports/indexreportseng.htm (accessed April, 2006).
- European AIDS Clinical Society. Guideliness for the clinical management and treatment of HIV infected adults in Europe antiretroviral agents in HIV-1-infected adults and adolescents. Revised Nov, 2008.
- Evan Wood, et al. Highly Active Antiretroviral Therapy and Survival in HIV-infected Injection Drug Users // JAMA. 2008. — 300(5):550−554
- Fetkenheuer G., et al. Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection // N. Engl. J. Med. 2008. — 359:1442−1455.
- Fidler S., et al. Slower CD4 Cell Decline Following Cessation of a 3 Month Course of HAART in Primary HIV Infection: Findings From an Observational Cohort // AIDS. 2007. — 21(10):1283−1291
- Fiona M. Ewings, et al. Survival Following HIV Infection of a Cohort Followed up From Seroconversion in the UK // AIDS. 2008. — 22(l):89−95
- Fischl M., et al. Impact of directly observed therapy on long-term outcomes in HIV clinical trials // 8th Conference on Retroviruses and Opportunistic Infections (CROI), Chicago, 4−8 February 2001 (Abstract 528).
- Fisher J.D., Fisher W.A., Amico K.R., et al. An information-motivation-behavioral skills model of adherence to antiretroviral therapy // Health Psyhol. 2006. — 25- 462 — 473.
- Forns X, Costa J. HCV virological assessment // Journal of Hepatology. 2006. — 44(S1):S40-S43.
- Frank J. Palella Jr., The Association of HIV Susceptibility Testing With Survival Among HIV-infected Patients Receiving Antiretroviral Therapy: A Cohort Study // Ann Intern Med. 2009. — 151:73−84.
- Freedberg K. A., Hirschhorn L. R., Schackman B. R., et al. Cost-Effectiveness of an Intervention to Improve Adherence to Antiretroviral Therapy in HIV-infected Patients // J. Acquir. Immune Defic. Syndr. 2006.- 43: S113-S118.
- Friedland G., Williams A. Attaining higher goals in HIV treatment: the central importance of adherence // AIDS. 1999. — 13 (Suppl.), S61 -S72.
- Fumaz C.R., et al. Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. J. Acquir. Immune Defic. Syndr. 2002. — 29(3):244−253.
- Gallant J. E., et al. Tenofovir D. F., emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV // N. Engl. J. Med. 2006. -354 (3), 251 -260.
- Garcia de Olalla P., Knobel H., Carmova A., et al. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J. Acquir. Immune Defic. Syndr. 2002. — 30, 105 — 110.
- Gathe Jr J.C., et al. Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatmentexperienced HIV type 1-infected patients // AIDS Research and Human Retroviruses. 2007. — 23(2):216−223.
- Gilks C.F., et al. The WHO public-health approach to antiretroviral treatment against HIV in resourcelimited settings // Lancet. 2006. -368(9534): 505−510.
- Glasgow R.E., Davidson K.W., Dobkin P.L., et al. Practical behavioral trials to advance evidence-based behavioral medicine // Ann. Behav. Med.- 2006.-31,5 13.
- Goetghebuer Tessaa, et al. Effect of early antiretroviral therapy on the risk of AIDS/death in HIV5infected infants: ART before age 3 months dramatically reduces AIDS/death // AIDS. 2009. — Vol. 23 (5) — 597−604.
- Goetz M.B., Ferguson M.R., Han X., et al Evolution of HIV Resistance Mutation in Patients Maintained on Stable Treatment Regimen After Virologie Failure // J. Acquir. Immune Defic. Syndr. 2006. -43:541 -549.
- Golin C., Honghu L., Hays R., et al. A prospective study of predictors of adherence to combination antiretroviral medication // J Gen Intern Med. -2002. 17:756−765.
- Golin C.E., Smith S.R., Reif S. Adherence counseling practices of generalist and specialist physicians caring for people living with HIV/AIDS in North Carolina // J Gen Intern Med. 2004. — 19(l):16−27.
- Gordillo V., del Arno J., Soriano V., et al. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy // AIDS. 1999. — 13(13):1763−1769.
- Graber S., et al. Clinical outcome of patients with HIV-1 infection according to immunological and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med. 2000. — 133:401−410.
- Granich R.M., Gilks C.F., Dye C., et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model // Lancet. 2009. — 373(9657):48−57.
- Grant G.M., et al. Declining nucleoside reverse transcriptase inhibitor primary resistance in San Francisco 2000−2002 // 12th International Drug
- Resistance Workshop, Los Cabos, Mexico, 10−13 June 2003 (Abstract 120).
- Gras L., et al. Predictors of changes in CD4 cell count seven years after starting start // 13th Annual Conference on Retroviruses and Opportunistic Infections (13th CROI), Denver, 5−8 February 2006 (Abstract 530).
- Gregory K. Robbins, et al. Predictors of Antiretroviral Treatment Failure in an Urban HIV Clinic // J Acquir Immune Defic Syndr. 2007. -44:30−37
- Grinztejn B., Nguen B.-Y., Katlama C., et al. Potent antiretroviral effect of MK 0518, a novel HIV-1 integrase inhibitor, in patients with triplethclass resistant virus //13 Conference on Retroviruses and Opportunistic Infections, 2006, Denver.
- Gulick R.M., et al. Maraviroc for Previously Treated Patients with R5 HIV-1 Infection//N. Engl. J. Med. -2008. 359:1429−1441.
- Gupta R., et al. Emergence of Drug Resistance in HIV Type 1 Infected Patients after Receipt of First-Line Highly Active Antiretroviral Therapy: A Systematic Review of Clinical Trials // Clin. Infect. Dis. — 2008. -47, 712−722.
- Hammer S.M., Saag M.S., Schechter M., et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS SocietyUSA panel // JAMA. 2006. — 296(7):827−43.
- Harrison K.M., et al. Life expectancy after HIV diagnosis based on national surveillance data from 25 states, United States // J Acquir Immune Defic Syndr. 2010. — Volume 53 — Issue 1 — pp 124−130.
- Havlir D.V., et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens // JAMA. 2000. — 283(2):229−234.
- Havlir D.V., Getahun H., Sanne I., et al. Opportunities and challenges for HIV care in overlapping HIV and ТВ epidemics // JAMA. 2008. -300(4):423−30.
- Hernandez В., Moreno S., PerezElias M.J. Тяжесть побочных эффектов при применении комбинации антиретровирусных препаратов диданозина и ставудина у больных ВИЧ инфекцией с опытом прохождения АРВТ // J. Acquir. Immune Defic. Syndr. 2006. — 43:556−559.
- Hill A., et al. How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials // AIDS. -2009.-23(17):2237−45
- Hirsch H. H., et al. Immune reconstitution in HIV-infected patients // Clin. Infect. Dis. 2004. — 38: 1159.
- Hunt P.W., et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy // AIDS. 2003. — 17:1907−1915.
- Jacobson M.A., et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy // Lancet. 1997. — 349(9063): 1443−1445.
- Jager J., et al. Hepatitis C and injecting drug use: impact, costs and policy options // Lisbon, European Monitoring Centre for Drugs and Drug Addiction, 2004 (EMCDDA Monographs).
- Jeffrey H. Samet, et al. Alcohol Consumption and HIV Disease Progression. The Journal of Infectious Diseases. 2007. — 195(6): 847−56
- Jennifer H. Tai, et al. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy. The Journal of Infectious Diseases.-2007. 196:1044−52.
- Johnson M., et al. A Once-Daily Lopinavir/ Ritonavir-Based Regimen Provides Noninferior Antiviral Activity Compared With a Twice-Daily Regimen // J Acquir Immune Defic Syndr. 2006. — 43:153−160
- Kalichman S.C., Ramachandran B., Catz S. Adherence to combination antiretroviral therapies in HIV patients of low health literacy // J Gen Intern Med. 1999. — 14:267−273.
- Kassuto S., et al. Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection // Clin. Infect. Dis. 2006. — 42, 1024 — 1031.
- Keiser O., Tweya H., Braitstein P., et al. Mortality after failure of antiretroviral therapy in sub-Saharan Africa // Trop Med Int Health. 2009. — 15:2,251−258.
- Kenneth A. Lichtenstein et al. Initiation of Antiretroviral Therapy at CD4 Cell Counts = 350 cells/mmi Does Not Increase Incidence or Risk of Peripheral Neuropathy, Anemia, or Renal Insufficiency // J Acquir Immune Defic Syndr. 2008. — 47:2735.
- Keraly J., et al. Increasis in CD4 cell count to five years in personswith sustained virologie suppression // 13th Annual Conference on Retrovithruses and Opportunistic Infections (13 CROI), Denver, 5−8 February 2006 (Abstract 529).
- Khanna N., et al. CD4 T-cell Count Recovery in HIV Type 1 Infected Patients Is Independent of Class of Antiretroviral Therapy // Clin. Infect. Dis. -2008. — 47: 1093 — 1101.
- Kholoud P., et al. Changes in Outcome of Persons Initiating Highly Active Antiretroviral Therapy at a CD4 Count Less Than 50 Cells/mm3 // AIDS. 2008. — 47, 202−205.
- Kitahata M.M., et al. Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival // N. Engl. J. Med. 2009. — 360:1815−26.
- Kleinman A., Eisenberg L., Good B. Clinical lessons from anthropologic and cross-cultural research // Ann. Intern. Med. 1978. — 88, 251 -258.
- Koroneos G. Patients Spurn AIDS Drugs Die to Side Effects // PharmExec, 2008.
- Kousignian I., et al. Maintaining Antiretroviral Therapy Reduces the Risk of AIDSDefining Events in Patients with Uncontrolled Viral Replication and Profound Immunodeficiency // Clin. Infect. Dis. 2008. — 46:296— 304.
- Koval C.E., et al. Immune reconstitution syndrome after successful treatment of Pneumocystis carinii pneumonia in a man with human immunodeficiency virus type 1 infection // Clin. Infect. Dis. 2002. — 35(4):491−493.
- Labarga P., et al. Hepatotoxity of Antiretroviral Drugs Is Reduced after Succesful treatment of Chronic Hepatitis C in HIV-infected Patients // The Journal of Infectious Diseases. 2007. — 196: 670 — 676.
- Lafeuillade A., Hittinger G., Chapadaud S. Increased mitochondrial toxicity with ribavirin in HIV-HCV coinfection // Lancet. 2001. — 357:280 281.
- Laguno M., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV coinfected patients // AIDS. 2004. — 18: F27-F36.
- Lawn S.D., Churchyard G. Epidemiology of HIV-associated tuberculosis // Curr Opin HIV AIDS. 2009. — 4(4):325−33.
- Lawrence J., Hullsiek K.H., Thackeray L. Disadvantages of Structured Treatment Interruption Persist in Patients With Multidrug-Resistant ITIV-1: Final Results of the CPCRA 064 Study AIDS // J. Acquir. Immune Defic. Syndr.-2006.-43:169−178.
- Lazzarin A., et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia // N. Engl. J. Med. 2003. -348(22):2186 — 2195.
- Le Moing V., et al. Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen // Journal of Infectious Diseases. 2002. — 185(4):471−480.
- Ledergerber B. The PLATO Collaboration. Predictors of trend in CD4-positive T-cell count and mortality among HIV-l infected individualswith virological failure to all three antiretroviral-drug classes // Lancet. -2004.-364:51−62.
- Lerner B.H., Gulick R.M., Dubler N.N. Rethinking nonadherence: historical perspectives on triple-drug therapy for HIV disease // Ann Intern Med. 1998. — 129(7):573−578.
- Levine A.J., Hinkin C.H., Castellon S.A., et al. Variations in patterns of highly active antiretroviral therapy (HAART) adherence // AIDS Behav. 2005. — 9(3):355−62.
- Lewden C. Responders to antiretroviral treatment over 500 CD4/mm3 reach same mortality rates as general population: APRICO and Aquitaine Cohorts // 10th European Aids Conference, Dublin, 17 20 November, 2005 (Abstract PE 18.4/8).
- Lewin S.R., Rouzioux C. «HIV cure and eradication: how will we get from the laboratory to effective clinical trials?» // AIDS. 2011. -25(7):885−97.
- Lima V.D., Hogg R.S., Harrigan P.R., et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy // AIDS. 2007. — 21 (6): 685−92.
- Little S.J., et al. Antiretroviral-drug resistance among patients recently infected with HIV // N. Engl. J. Med. 2002. — 347(6):385−394.
- Liu H., et al. A comparison study of multiple measures of adherence to HIV protease inhibitors // Ann Intern Med. 2001. — 134(10):968−977.
- Liu H., Miller L. G., Hays R. D., et al. A Practical Method to Calibrate Self-Reported Adherence to Antiretroviral Therapy // J. Acquir. Immune Defic. Syndr. 2006. — 43: S104-S112.
- Lockman S., Shapiro R.L., Smeaton L.M., et al. Response to Antiretroviral Therapy after a Single, Peripartum Dose of Nevirapine // N. Engl. J. Med.-2007.-356:135−4.
- Lohse N., et al, Survival of Persons with and without HIV Infection in Denmark, 1995−2005 // Ann Intern Med. 2007. — 146:87−95
- Maggiolo F., Ripamonti D., Arici C., et al. Simpler regimens may enhance adherence to antiretroviral in HIV-infected patients // HIV Clin Trials. 2002. — 3(5):371−8.
- Maher K., et al. Disease progression, adherence and response to protease inhibitor therapy for HIV infection in an Urban Veterans Affairs Medical Center // J Acquir Immune Defic Syndr. 1999. — 22(4):358−363.
- Maida I., Nunez M., Rios M.J., et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs // J. Acquir. Immune Defic. Syndr.-2006.-42:177−182.
- Mannheimer S., Friedland G., Matts J., et al. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus infected persons in clinical trials. Clin. Infect. Dis. -2002.-34, 1115−1121.
- Mannheimer S.B., Morse E., Matts J.P., et al. Sustained Benefits From a Long-Term Antiretroviral Adherence Intervention: Results of a Large Randomized Clinical Trial // J. Acquir. Immune Defic. Syndr. 2006. -43:S41-S47
- Manosuthi W.S., Chottanapand S., Thongyen A., et al. Survival Rate and Risk Factors of Mortality Among HIV/Tuberculosis Coinfected Patients With and Without Antiretroviral Therapy // J Acq Immun Def Syndrome. -2006.-43:42−6.
- Marchou B., et al. Structured treatment interruptions in HIV-infected patients with high CD4 cell counts and virologic suppression: results of a prospective, randomized, open-label trial (Window ANRS 106) // 13th
- Annual Conference on Retroviruses and Opportunistic Infections (CROI), Denver, 5−8 February 2006 (Abstract 104).
- Marin Beno’t, et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy // AIDS. 2009. -23(13): 1743−1753.
- Markowitz M., et al. Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients with HIV-1 Infection. Results of a 48-week Controlled Study // AIDS. 2007. — 0, 1−9.
- Markowitz M., Nguen B.-Y., Gottuzo E., et al. Potent antiretroviral effect of MK 0518, a novel HIV-1 integrase inhibitor, as part of combination ART in treatment-naive HIV-1 infected patients // XVI International AIDS Conference, 2006, Toronto.
- Mauss S. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy // AIDS. 2004. — 18(13):F21—25.
- Mauss S. Treatment of viral hepatitis in HIV-coinfected patients-adverse events and their management // J. Hepatol. 2006. — 44 (Suppl.), SI 14 — 118.
- Max B., Sherer R. Management of the adverse effects of antiretroviral therapy and medication adherence // Clin. Infect. Dis. 2000. — 30 Suppl 2: S96-S116.
- May M., Sterne J., Sabin. Prognosis of HIV-1-infected Patients Up to 5 years After Initiation of HAART: Collaborative Analysis of Prospective Studies. The Antiretroviral Therapy (ART) Cohort Collaboration // AIDS. -2007. 21(9):1185−1197.
- McComsey G., Lonergan J.T. Mitochondrial dysfunction: patient monitoring and toxicity management // J Acquir Immune Defic Syndr. -2004. 37 Suppl l: S30−5.
- Michael J. Silverberg, et al. Older Age and the Response to and Tole-rability of Antiretroviral Therapy. Ann Intern Med. 2007. — 167:684−691.
- Miller L.G., Golin C.E., Hays R.D., et al. Impact of antiretroviral regimen switches on adherence // HIV Clin Trials. 2002. — 3(5):355−360.
- Miller L.G., Liu H., Hays R.D., et al. How well do clinicians estimate patient’s adherence to combination antiretroviral therapy? // J Gen Intern Med.-2002. 17:1−11.
- Miller M.D., Witmer M.V., Stillmock K.A., et al. Biochemical and antiviral activity of MK-0518, a potent HIV integrase inhibitor // 13th Conference on Retroviruses and Opportunistic Infections- 2006- Denver.
- Moh R., Danel C., Messou E., et al. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa // AIDS. 2007. -21(18):2483−91.
- Monforte Antonella d’Arminio, et al. Risk of Developing Specific AIDS-Defining Illnesses in Patients Coinfected with HIV and Hepatitis C Virus With or Without Liver Cirrhosis // Clin. Infect. Dis. 2009. — 49:612 622.
- Montgomery K. How Doctors Think: Clinical Judgment and the Practice of Medicine New York: Oxford University Press- 2006.
- Moore A.L., et al. Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure?//AIDS. 2002. — 16(4):615−618.
- Moore D.M., et al. Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients inresource-limited settings // J. Acquir. Immune Defic. Syndr. 2006. -43:436−439.
- Moreno A., et al. High rate of didanosine-related mitochondrial toxicity in HIV-HCV coinfected patients receiving didanosine // Antiviral Therapy. 2004. — 9:133−138.
- Mulcahy F., et al. CD4 counts in pregnancy do not accurately reflectLthe need for long-term HAART // 13 Annual Conference on Retroviruses and Opportunistic Infections (13th CROI), Denver, 5−8 February 2006 (Abstract 704b).
- Murri R., Ammassari A., Trotta M.P., et al. Patient-reported and physician-estimated adherence to HAART // J Gen Intern Med. 2004. -19:1104−1110.
- Murri R., et al. Is moderate HIV viremia associated with a higher risk of clinical progression in HIV-infected people treated with highly active antiretroviral therapy // J. Acquir. Immune Defic. Syndr. 2006. — 41(1):23−30.
- Myron S. Cohen, Ying Q. Chen, Marybeth McCauley, et al. Prevention of HIV-1 Infection with Early Antiretroviral Therapy // N. Engl. J. Med.-2011.-365:493−505.
- Neau D., et al. Prevalence of and factors associated with hepatic steatosis in patients coinfected with hepatitis C virus and HIV // J. Acquir. Immune Defic. Syndr. 2007. — 45:168−173.
- Nettles R.E., et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART // JAMA. 2005. — 293(7):817−829.
- Niel Malan D.R., et al. Efficacy and Safety of Atazanavir, With or Without Ritonavir, as Part of Once-Daily Highly Active Antiretroviral Therapy Regimens in Antiretroviral-Naive Patients // AIDS. -2008. 47(2), 161— 167.
- Nunez M., Soriano V. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management // Drug Safety. 2005. — 28(1):53−66.
- Oette M., Kaiser R., Daumer M., et al. Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing // J. Acquir. Immune Defic. Syndr. 2006. — 41: 573 — 581.
- Oldfield V., Keating G.M., Plosker G. Enfuvirtide: a review of its use in the management of HIV infection // Drugs. 2005. — 65(8): 1139−1160.
- Opravil M., et al. Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count >350×10(6) // AIDS. 2002. — 16(10):1371 — 1381.
- Osterberg L., Blaschke T. Adherence to Medication // N Engl J Med. -2005.-353:487−97.
- Palella F.J. Jr, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators //N. Engl. J. Med. 1998. — 338(13):853 — 860.
- Palella F.J., Chmiel J.S., Moormana A.C., et al. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients // AIDS. 2002. — 16:1617−1626.
- Palella F.J., Delaney K.M., Moorman A.C. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection // N. Engl. J. Med. 1998. — 338:853−860.
- Palella F.J., et al. Mortality in the Highly Active Antiretroviral Therapy Era: Changing Causes of Death and Disease in the HIV Outpatient Study // J. Acquir. Immune Defic. Syndr. 2006. — 43: 27−34.
- Parienti J.-J., et al. Better Adherence with OnceDaily Antiretroviral Regimens: A Meta-Analysis // Clin. Infect. Dis. 2009. — 48, 484188.
- Parienti J.J., et al. The pills identification test: a tool to assess adherence to antiretroviral therapy // JAMA. 2001. — 285(4):412.
- Patel S.M., et al. Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J. Acquir. Immune Defic. Syndr. 2004. — 35(2): 120−125.
- Paterson D., Swindells S., Mohr J., et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection // Ann. Intern. Med. -2000.- 133,21 -30.
- Pates K., et al. Long-Term Effects of Highly Active Antiretroviral Therapy on CD4+ Cell Evolution among Children and Adolescents Infected with HIV: 5 years and Counting // Clin. Infect. Dis. 2008. — 46, 1751 -1760.
- Payne B., Wilson I., Hateley C., et al. Mitochondrial aging is accelerated by anti-retroviral therapy through the clonal expansion of mtDNA mutations. Nature Genetics, 2011
- Perelson A.S., et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time // Science. 1996. -271(5255): 1582−1586.
- Petersen M.L., et al. Long-term consequences of the delay between Virologie failure of highly active antiretroviral therapy and regimen modification // AIDS. 2008. — 22, 2097.
- Powell K., et al. Survival for Patients With HIV Admitted to the ICU Continues to Improve in the Current Era of Combination Antiretroviral Therapy // Chest. 2009. — 135, 11−17.
- Poynard T., et al. A comparison of fibrosis progression in chronic liver diseases // Journal of Hepatology. 2003. — 38:257−265.
- Protocol for evaluation of transmitted HIV drug resistance using specimens from HIV sentinel serosurveys in resource-limited settings (Draft). Geneva, WHO, 2006 (http://www.who.int/entity/hiv/drugresistance/
- Pulido F., et al. Lopinavir/ritonavir monotherapy versus lopina-vir/ritonavir and two nucleosides for maintenance therapy of HIV // AIDS. -2008. 22 (2): F1-F9.
- Quereda C., Corral I., Moreno A., et al. Effect of treatment with efavirenz on neuropsychiatrie adverse events of interferon in HIV/HCVcoinfected patients // J. Acquir. Immune Defic. Syndr. 2008. -49:61−63.
- Race E.M., et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease // Lancet. 1998. — 351(9098):252−255.
- Reed C., Daar E.S. Novel Antiretroviral Agents in HIV Therapy // Curr Infect Dis. 2006. — 8(6):489−96.
- Remien R., Stirratt M., Dognin J., et al. Moving from theory to research to practice. Implementing an effective dyadic intervention to improve antiretroviral adherence for clinic patients // J. Acquir. Immune Defic. Syndr. 2006. — 43: S69-S78.
- Resistance Orientation to WHO Methodology for surveillance of transmitted HIV Drug Resistance. Geneva, WHO, 2006 (http://www.who.int/hiv/drugresistance/ HIVDRSurveillance2006. ppt#294
- Rey D., Hoen B., Chavanet P., et al. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients // J Antimicrob Chemother. 2009. -63(2):380−8.
- Rockstroh J.K., et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy // Journal of Infectious Diseases. 2005. — 15, 192(6):992−1002.
- Ross L.L., Parkin N., Gerondelis P., et al. Differential Impact of Thymidine Analogue Mutations on Emtricitabine and Lamivudine Susceptibility // J. Acquir. Immune Defic. Syndr. 2006. — 43:567−570.
- Saag M., et al. A Double-Blind, Placebo-Controlled Trial of Maravi-roc in Treatment-Experienced Patients Infected with Non-R-HIV-1 // J Infect Dis. 2009. — 199 (11), 1638−1647.
- Sackoff J.E., et al. Causes of Death among Persons with AIDS in the Era of Highly Active Antiretroviral Therapy: New York City // Ann Intern Med.-2006. 145:397−406
- Safren S.A., et al. Two strategies to increase adherence to HIV antiretroviral medication: life-steps and medication monitoring // Behaviour Research and Therapy. -2001. (10):1151−1162.
- Saitoh A., et al. Clinical Outcomes After an Unstructured Treatment Interruption in Children and Adolescents With Perinatally Acquired HIV Infection // Pediatrics. 2008. — 121- e513-e521.
- Salmon D., et al. Therapeutic management of hepatitis and HIV infection in coinfected patients: results of a survey performed before the 2005 Consensus Conference // Journal of Hepatology. 2006. — 44(S1): S2-S5.
- Salmon-Ceron D., et al. Liver disease as a major cause of death among HIV-infected patients: roles of hepatitis C and B viruses and alcohol // Journal of Hepatology. 2005. — 42: 799−805.
- Salmon-Ceron D., et al. Mitochondrial toxic effects of ribavirin // Lancet.-2001. -357:1803.
- Salmon-Ceron., et al. Hospitalized HIV-HCV coinfected patients. A French national survey made in June 2001 // Medecine et maladies infectieuses. 2003. — 33:78−83.
- Sanchez-de la Rosa R., Herrera L., Moreno S. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviralnaive, HIV-1-infected patients // Clin Ther. 2008. — 30(2):372−81.
- Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach: 2003 revision. Geneva, World Health Organization, 2004.
- Servoss J., Kitch D.W., Andersen J. New Risk Factors: Predictors of Antiretroviral-Related Hepatotoxicity in the Adult AIDS Clinical Trial Group (1989−1999) // J. Acquir. Immune Defic. Syndr. 2006. — 43:320 323.
- Sheran M. The nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in the treatment of HIV // HIV Clinical Trials. 2005. -6(3):158- 168.
- Shet A., Berry L., Mohri H., et al. Tracking the prevalence of transmitted antiretroviral drug-resistant HTV-l-a decade of experience // J. Acquir. Immune Defic. Syndr. 2006. — 41- 439 — 446.
- Siegfried N.L., Rutherford G.W. Optimal time for initiation of antiretroviral therapy for asymptomatic, HIV-infected, treatment-naive adults // Cochrane Database of Systematic Reviews 2010. 2010(Issue 2 (In press)).
- Silverberg M.J., et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study // AIDS. 2007. — 21, 1957−1963.
- Simoni J.M., et al. Antiretroviral adherence interventions: a review of current literature and ongoing studies // Topics in HIV Medicine. 2003. -11(6): 185—198.
- Skiest D., et al. Predictors of HIV disease progression in patients who stop ART with CD4 cell counts >350 cells/mm3 // 13th Annual Conference on Retroviruses and Opportunistic Infections (CROI), Denver, 5−8 February 2006 (Abstract 101).
- Slim J., et al. Saquinavir/r BID vs. Lopinavir/r plus FTC/Tenofovir QD in ARV-nafve HIV-1-infected patients: GEMINI study // 8th International Congress on Drug Therapy in HIV infection, Glasgow, Scotland, UK, 12- 16 November 2006.
- Smith C.J., et al. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy // Journal of Infectious Diseases. 2004. — 190(10): 1860−1868.
- Soriano V. Treatment of chronic hepatitis C in HIV-positive individual: Selection of candidates // J. Hepatol. 2006. — 44, S44 — S48.
- Soriano V., et al. Treatment of Chronic Hepatitis B or C in HIV-infected Patients with Dual Viral Hepatitis // The Journal of Infectious Diseases. 2007. — 195:1181−3
- Starace F., Massa A., Amico K.R., et al. Adherence to antiretroviral therapy: an imperisial test of the information-motivation-behavioral skills model // Health Psyhol. 2006. — 25- 153 — 162.
- Steigbigel R.T., Cooper D.A., Kumar P.N., et al. Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection // N. Engl. J. Med.-2008. -359:339−54.
- Sterne J.A., et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study // Lancet. 2005. — 366(9483):378 — 384.
- Sterne J.A., May M., Costagliola D. de Wolf F, et al. Timing of initiation of antiretroviral therapy in AiDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies // Lancet. 2009. -373(9672): 1352−63.
- Stone V. Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice // Clin. Infect. Dis.-2001. 33:865−872.
- Subbaraman R., Chaguturu S.K., Mayer K.H., et al. Adverse effects of highly active antiretroviral therapy in developing countries // Clin. Infect. Dis.-2007.-45(8): 1093−101.
- Sulkowski M. S. Treatment algorithm for the management of hepatitis C in ШУ-coinfected persons // J. Hepatol. 2006. — 44- S49 — S55.
- Sulkowski M.S., et al. Rapid fibrosis progression among HIV/hepatitis C virus coinfected adults // AIDS. 2007. — 21, 2209−2216.
- Sulkowski M.S., Thomas D.L. Hepatitis C in the HIV-infected patient // Clinical Liver Disease. -2003. 7(1): 179−194.
- Summa V., Pace P., Petrocci A., et al. Discovery of MK-0518 a novel, potent and selective HIV integrase inhibitor in phase III clinical trials // th
- AIDS 16 International Conference, 2006, Toronto.
- Tan D. H., Chan K., et al. Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy // J Acquir Immune Defic Syndr. 2011. — 58(l):38−46.
- Tedaldi E.M.,, Brooks J.T., Paul J. Increased Body Mass Index Does Not Alter Response to Initial Highly Active Antiretroviral Therapy in HIV 1 Infected Patients // J. Acquir. Immune Defic. Syndr. 2006. — 43:3541.
- Tedalti E., et al. Opportunistic Disease and Mortality in Patients Coinfected with Hepatitis В or C Virus in the Strategic Management of Antiretroviral Therapy (SMART) Study // Clin. Infect. Dis. 2008. — 47, 1468 -1475.
- Thio C.L., et al. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals // Journal of Clinical Microbiology.2000. 38(2):575−577.
- Torriani F.J., et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients // N. Engl. J. Med. -2004.-351:438−450.
- U.S. Department of Health and Human Serrius. Guideliness for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 10 Oct, 2008.
- Uberti-Foppa C., De Bona A., Galli L., et al. Liver fibrosis in HIVpositive patients with hepatitis C virus: role of persistently normal alanine aminotranserase levels // J. Acquir. Immune Defic. Syndr. 2006. — 41, 63 -67.
- UK Collaborative Group on Monitoring the Transmission of HIV. Drug resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom // BMJ. 2001. — 322(7294): 1087−1088.
- UNAIDS. Cost Estimates: AIDS Financing and Economics. 2009.
- Uy J., et al. Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure // J Acquir Immune Defic Syndr. 2009. — 51:450.
- Valerio L., Yazdanpanah Y., Poizot-Martin I., et al. Baseline CD4 cell count and outcome of pegylated interferon plus ribavirin therapy in HIV/hepatitis C virus-coinfected patients // J. Acquir. Immune Defic. Syndr. -2008.-47:50−5.
- Vallet-Pichard A, Pol S. Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) coinfection // Journal of Hepatology. 2006. — 44(S1):S28-S34.
- Van Asten L, Prins M. Infection with concurrent multiple hepatitis C virus genotypes is associated with faster HIV disease progression // AIDS. -2004. 18(17):2319−2324.
- Van Lunzen J., Maggiolo F., Phung B., et al. «Rapid, robust and sustained antiviral response with once-daily (QD) dolutegravir (DTG,
- Vanhove G.F., et al. Patient compliance and drug failure in protease inhibitor monotherapy // JAMA. 1996. — 276(24): 1955−1956.
- Ventura J., Wenning L.A., Troyer M.D., et al. Lack of a pharmacokinetic interaction of MK-0518 on midazolam (MDZ) // Eight International Congress on Drug Therapy in HIV infection, 2006, Glasgow.
- Violari A., et al. Early Antiretroviral Therapy and Mortality among HIV-infected Infants // N. Engl. J. Med. 2008. — 359, 2233−2244.
- Walensky R.P., et al. The Survival Benefits of AIDS Treatment in the United States // JID. 2006. — 194:11−19
- Walmsley S., Avihingsanon A., Slim J. Gemini: A Noninferiority Study of Saquinavir/Ritonavir Versus Lopinavir/Ritonavir as Initial HIV1 Therapy in Adults // J. Acquir. Immune Defic. Syndr. 2009. — 50:367−374.
- Walsh J.C., et al. An assessment of current HIV treatment adherence services in the UK // AIDS Care. 2002. — 14(3):329−334.
- Walsh J.C., et al. Reasons for non-adherence to antiretroviral therapy: patients' perspectives provide evidence of multiple causes // AIDS Care. -2001. 13(6):709−720.
- Weber R., et al. Effect of individual cognitive behaviour intervention on adherence to antiretroviral therapy: prospective randomized trial // Antiviral Therapy. 2004. — 9(l):85−95.
- When To Start Consortium Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies // Lancet. 2009. — 373, 1352−1363.
- WHO antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach 2006 revision // Geneva, WHO, 2006.
- Wilkin T.J., Gulic R.M. When to Start Antiretroviral Therapy? // Clin. Infect. Dis. 2008. — 47, 1580 — 1586.
- Williams A.B., Fennie K.P., Bova C.A., et al. Home Visits to Improve Adherence to Highly Active Antiretroviral Therapy: A Randomized Controlled Trial // J. Acquir. Immune Defic. Syndr. 2006. — 42:314−321
- Wilson D., Keiluhu A.K., Kogrum S., et al. HIV-1 viral load monitoring: an opportunity to reinforce treatment adherence in a resource-limited setting in Thailand // Med Hyg. 2009. — 103(6):601−6.
- Wong K.H., Chan K.C., Cheng K.L., et al. Establishing CD4 thresholds for highly active antiretroviral therapy initiation in a cohort of HIV-infected adult Chinese in Hong Kong // AIDS Patient Care STDS. -2007.-21(2):106−15.
- Wood E., Hogg R., Yip B., et al. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4 cell count is 0.200 to 0.350×10 (9) cells/L. Ann. Intern. Med.-2003. 139, 810−816.